Compare · FLDM vs RVTY
FLDM vs RVTY
Side-by-side comparison of Fluidigm Corporation (FLDM) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- FLDM operates in Capital Goods, while RVTY operates in Industrials - the two are in different parts of the market.
- RVTY is the larger of the two at $10.97B, about 44.9x FLDM ($244.6M).
- RVTY has hit the wire 2 times in the past 4 weeks while FLDM has been quiet.
- RVTY has more recent analyst coverage (19 ratings vs 0 for FLDM).
- Company
- Fluidigm Corporation
- Revvity Inc.
- Price
- $3.70-7.27%
- $101.06+2.67%
- Market cap
- $244.6M
- $10.97B
- 1M return
- -
- +2.22%
- 1Y return
- -
- +8.82%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 19
Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF XT. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Latest FLDM
- No More Free COVID-19 At-Home Tests, Federal Government Says
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units
- SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units
- SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Witney Frank was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Paya Carlos V was granted 30,914 shares, increasing direct ownership by 44% to 100,468 units
- SEC Form 4: Casdin Eli was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Clague Laura was granted 30,914 shares, increasing direct ownership by 65% to 78,415 units
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)